Treatment of Soft Tissue Infections Due to Intravenous Drug Use
Initial Assessment and Microbiology
- The location of injection, presence of necrosis, systemic symptoms, and depth of infection should guide treatment approach 3
Empiric Antibiotic Therapy
- The Infectious Diseases Society of America recommends vancomycin 15 mg/kg IV q12h for MRSA coverage plus a broad-spectrum beta-lactam antibiotic for gram-negative coverage, with duration of 7-14 days based on clinical response 1, 2
- Piperacillin-tazobactam 3.37g IV q6-8h is recommended for gram-negative coverage 3
- Cefotaxime 2g IV q6h plus metronidazole 500mg IV q6h is an alternative option for gram-negative coverage 3
Duration of Therapy
- 7-14 days of antibiotic therapy is recommended for most soft tissue infections 1, 2
- For complicated infections with deep tissue involvement or osteomyelitis, longer courses (4-6 weeks) may be necessary 6, 7
Surgical Management
- Incision and drainage is critical for abscesses 3
- Necrotic tissue should be debrided promptly 3
- For necrotizing infections, aggressive surgical debridement is essential for survival 5
Special Considerations
- In patients with severe penicillin allergies, consider clindamycin plus either an aminoglycoside or fluoroquinolone 3
- For necrotizing infections, add clindamycin (600-900 mg IV q8h) to decrease toxin production, particularly for group A streptococcal infections 3
Common Pitfalls to Avoid
- Failing to consider MRSA coverage in IV drug users (high prevalence population) 1
- Prolonged IV therapy when oral options with good bioavailability (like linezolid) are available and the patient is clinically stable 1, 2